Based on the Thyrocare Technologies Limited stock forecast from 0 analysts, the average analyst target price for Thyrocare Technologies Limited is not available over the next 12 months. Thyrocare Technologies Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Thyrocare Technologies Limited is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Thyrocare Technologies Limited’s stock price was INR 973.00. Thyrocare Technologies Limited’s stock price has changed by +3.61% over the past week, +37.31% over the past month and +49.74% over the last year.
No recent analyst target price found for Thyrocare Technologies Limited
No recent average analyst rating found for Thyrocare Technologies Limited
Company Overview Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical products. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited. Read Less
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles...Read More
Frequently Asked Questions About Thyrocare Technologies Limited (THYROCARE:NSE) Stock
Stock Target Advisor's fundamental analysis for Thyrocare Technologies Limited's stock is Slightly Bearish.
THYROCARE:NSE stock's dividend yield is 2.05%.
Our analysis grades THYROCARE:NSE stock's dividend yield at A+. This means that THYROCARE:NSE stock's dividend yield is above 100% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this THYROCARE:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on THYROCARE:NSE's stock to indicate what its average analyst target is.
THYROCARE:NSE stock's Price/Earning ratio is 51.29.
Our analysis grades THYROCARE:NSE stock's Price / Earning ratio at F. This means that THYROCARE:NSE stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this THYROCARE:NSE may be a overvalued for its sector.
The last closing price of THYROCARE:NSE's stock was INR 973.00.
The most recent market capitalization for THYROCARE:NSE is INR 46.53B.
Unfortunately we do not have enough analyst data on THYROCARE:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Thyrocare Technologies Limited's stock.
As per our most recent records Thyrocare Technologies Limited has 0 Employees.
Thyrocare Technologies Limited's registered address is D/37-3, TTC Industrial Area, Navi Mumbai, India, 400703.
You can get more information about it from Thyrocare Technologies Limited's website at https://www.thyrocare.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Thyrocare Technologies Limited (THYROCARE:NSE) Stock
Stock Target Advisor's fundamental analysis for Thyrocare Technologies Limited's stock is Slightly Bearish.
THYROCARE:NSE stock's dividend yield is 2.05%.
Our analysis grades THYROCARE:NSE stock's dividend yield at A+. This means that THYROCARE:NSE stock's dividend yield is above 100% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this THYROCARE:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on THYROCARE:NSE's stock to indicate what its average analyst target is.
THYROCARE:NSE stock's Price/Earning ratio is 51.29.
Our analysis grades THYROCARE:NSE stock's Price / Earning ratio at F. This means that THYROCARE:NSE stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this THYROCARE:NSE may be a overvalued for its sector.
The last closing price of THYROCARE:NSE's stock was INR 973.00.
The most recent market capitalization for THYROCARE:NSE is INR 46.53B.
Unfortunately we do not have enough analyst data on THYROCARE:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Thyrocare Technologies Limited's stock.
As per our most recent records Thyrocare Technologies Limited has 0 Employees.
Thyrocare Technologies Limited's registered address is D/37-3, TTC Industrial Area, Navi Mumbai, India, 400703.
You can get more information about it from Thyrocare Technologies Limited's website at https://www.thyrocare.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for THYROCARE:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
